相关实验视频
Updated: Jul 12, 2025

06:14
Translational Rabbit Model of Chronic Cardiac Pacing
Published on: January 6, 2023
2.6K
在患有先天性心脏病的患者中使用无起器
Elizabeth D Sherwin1, Maully J Shah2
1Division of Pediatric Cardiology, Children's National Hospital, Division of Cardiology Washington, 111 Michigan Avenue, NW, Washington, DC 20010, USA.
Cardiac electrophysiology clinics
|October 21, 2023
概括
无心脏起器为先天性心脏病患者提供了优势,通过避免并发症. 仔细的规划使成功的植入成为可能,解决了诸如访问和节奏需求等挑战.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 遗传性心脏病是一种先天性心脏病.
背景情况:
- 跨导管无心脏起器 (TLP) 通过消除与相关的并发症,在先天性心脏病 (CHD) 中提供优势.
- 传统的心脏起器带有诸如功能故障,静脉封闭和口袋感染等风险,TLP可以规避这些风险.
研究的目的:
- 评估在患有先天性心脏病的患者中使用最新的跨导管无心脏起器的可行性和考虑因素.
- 确定在这个复杂的患者群体中成功植入的挑战和关键因素.
主要方法:
- 在CHD解剖学的背景下,审查最新TLP系统的技术方面和局限性.
- 分析影响TLP植入的患者特异性因素,包括解剖学变异和并发症.
- 考虑程序规划,包括接入路径,植入点和抗凝策略.
主要成果:
- 最新的TLP的实用性受到其大型交付系统和特定步调要求的限制.
- 挑战包括进入肺下心室和缺乏探索选项.
- 成功的植入需要仔细规划,包括非大腿部接入和对植入部位的考虑.
结论:
- 尽管有局限性,但在先天性心脏病患者中,在精心计划的情况下,可以成功地进行无节奏.
- 关键考虑因素包括非大腿部接入,适当的植入部位选择,抗凝管理和操作人员的专业知识.
- 这种方法有望通过减轻与相关的风险来改善心血管疾病的器械治疗.
相关概念视频
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Mitral Stenosis III: Medical Management
12
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12
Mitral Stenosis I: Introduction
15
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
15
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11

